Показать сокращенную информацию
dc.contributor.author | Sigitova O. | |
dc.contributor.author | Kim T. | |
dc.contributor.author | Salmakova A. | |
dc.date.accessioned | 2020-01-15T22:12:52Z | |
dc.date.available | 2020-01-15T22:12:52Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 2191-1630 | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/157090 | |
dc.description.abstract | © 2019, Springer Science+Business Media, LLC, part of Springer Nature. Optimization of the choice of the treatment method, improving the prognosis of the immunoglobulin A nephropathy (IgAN). Seventy-six patients with morphologically confirmed IgAN from 21 to 73 years old (33.9 ± 1.2 years old, M/F = 47/29). There were analyzed the rates of progression of nephritis in these patients with a natural course of the disease and induced treatment, with a duration of nephropathy at 1 to 27 years (9.6 ± 0.9) in three groups with a different degree of activity of nephropathy. The natural rates of progression of IgA nephropathy are determined by its activity; the rate of progression of nephropathy increases with the increasing proteinuria (PU) and the greatest in patients with nephrotic proteinuria. Carrying out pathogenetic therapy, the choice which is determined by the activity of nephropathy helps to reduce the PU and slow the progression. In most patients, IgAN had a recurrent course. The frequency of relapses of IgAN did not depend on the pathogenetic therapy. | |
dc.relation.ispartofseries | BioNanoScience | |
dc.subject | IgA nephropathy | |
dc.subject | Nephroprotection | |
dc.subject | Rates of progression | |
dc.subject | The frequency of relapses | |
dc.subject | Treatment | |
dc.title | Flow Features of Immunoglobulin A Nephropathy Depending on Activity / Risk of Progression and Influence of Pathogenetic Therapy | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 2 | |
dc.relation.ispartofseries-volume | 9 | |
dc.collection | Публикации сотрудников КФУ | |
dc.relation.startpage | 495 | |
dc.source.id | SCOPUS21911630-2019-9-2-SID85066096261 |